Rein Therapeutics, Inc. (RNTX) stock
RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.36−0.00 (-0.31%)
Close on Nov 18, 2026Market cap $30.65MP/E –Yield 0.00%
Rein Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Rein Therapeutics's enterprise value was $8.35M on Nov 11, 2026, against $35.42M a year earlier. Over the last 5 years it ranged from -$20.81M to $67.18M, with a median of $15.05M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $8.35M | -66.8% |
| 2025 | Dec 31, 2025 | $25.11M | -22.0% |
| 2024 | Dec 31, 2024 | $32.18M | +1712.7% |
| 2023 | Dec 29, 2023 | $1.78M | – |
| 2022 | Dec 30, 2022 | -$14.71M | – |
| 2021 | Dec 31, 2021 | -$1.25M | -104.6% |
| 2020 | Dec 31, 2020 | $27.35M | – |
| 2019 | Dec 31, 2019 | -$8.63M | – |
| 2018 | Dec 31, 2018 | -$15.57M | -115.8% |
| 2017 | Dec 29, 2017 | $98.27M | – |
See a number that looks wrong?